{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:49:18Z","timestamp":1767649758893},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T00:00:00Z","timestamp":1433376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s12020-015-0639-1","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T02:37:22Z","timestamp":1433385442000},"page":"628-634","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Bisphosphonates and glucocorticoid-induced osteoporosis: cons"],"prefix":"10.1007","volume":"49","author":[{"given":"Willem F.","family":"Lems","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Saag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,4]]},"reference":[{"key":"639_CR1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF02938618","volume":"5","author":"JR Curtis","year":"2007","unstructured":"J.R. Curtis, K.G. Saag, Prevention and treatment of glucocorticoid-induced osteoporosis. Curr. Osteoporos. Rep. 5, 14\u201321 (2007)","journal-title":"Curr. Osteoporos. Rep."},{"key":"639_CR2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"R.S. Weinstein, Clinical practice. Glucocorticoid-induced bone disease. New Engl. J. Med. 365, 62\u201370 (2011)","journal-title":"New Engl. J. Med."},{"key":"639_CR3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-8587(13)70045-7","volume":"1","author":"MJ Seibel","year":"2013","unstructured":"M.J. Seibel, M.S. Cooper, H. Zhou, Glucocorticoid-induced osteoporosis: mechanisms, management and future perspectives. Lancet Diabetes Endocrinol. 1, 59\u201370 (2013)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"639_CR4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/14656566.2013.761975","volume":"14","author":"IEM Bultink","year":"2013","unstructured":"I.E.M. Bultink, M. Baden, W.F. Lems, Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin. Phamracother. 14, 185\u2013197 (2013)","journal-title":"Expert Opin. Phamracother."},{"issue":"1","key":"639_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/rheumatology\/37.1.27","volume":"37","author":"WF Lems","year":"1998","unstructured":"W.F. Lems, G.J. Van Veen, M.I. Gerrits et al., Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br. J. Rheumatol. 37(1), 27\u2013339 (1998)","journal-title":"Br. J. Rheumatol."},{"issue":"11","key":"639_CR6","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Staa van","year":"2003","unstructured":"T.P. van Staa, R.F. Laan, I.P. Barton et al., Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48(11), 3224\u20133229 (2003)","journal-title":"Arthritis Rheum."},{"key":"639_CR7","first-page":"1500","volume":"66","author":"JN Hoes","year":"2007","unstructured":"J.N. Hoes, J.W. Jacobs, M. Boers et al., EULAR-evidence based recommendations on the management of systemic glucocorticoid-therapy in rheumatic diseases. Ann. Rheum. Dis. 66, 1500\u20131507 (2007)","journal-title":"Ann. Rheum. Dis."},{"key":"639_CR8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"R. Caporali, M.A. Cimmino, G. Ferraccioli et al., Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann. Int. Med. 141, 493\u2013500l (2004)","journal-title":"Ann. Int. Med."},{"key":"639_CR9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"K Saag","year":"1998","unstructured":"K. Saag, R. Emkey, T.J. Schnitzer et al., Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. New Engl. J. Med. 339, 292\u2013299 (1998)","journal-title":"New Engl. J. Med."},{"key":"639_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(94)91049-9","volume":"8914","author":"AK Gough","year":"1994","unstructured":"A.K. Gough, J. Lilley, S. Eyre et al., Generalised bone loss in patients with early rheumatoid arthritis. Lancet 8914, 23\u201327 (1994)","journal-title":"Lancet"},{"issue":"11","key":"639_CR11","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","volume":"65","author":"M Vis","year":"2006","unstructured":"M. Vis, E.A. Havaardsholm, G. Haugeberg et al., Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65(11), 1495\u20131499 (2006)","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"639_CR12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/ard.2009.127787","volume":"70","author":"DA Eekman","year":"2011","unstructured":"D.A. Eekman, M. Vis, I.E. Bultink et al., Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70(2), 389\u2013390 (2011)","journal-title":"Ann. Rheum. Dis."},{"key":"639_CR13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/rheumatology\/kes320","volume":"52","author":"CL Krieckaert","year":"2013","unstructured":"C.L. Krieckaert, M.T. Nurmohamed, G. Wolbink et al., Changes in bone mineral density during long-term treatment with adalimumab in RA-patients: a cohort study. Rheumatology 52, 547\u2013553 (2013)","journal-title":"Rheumatology"},{"key":"639_CR14","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/ket468","volume":"53","author":"K Kume","year":"2014","unstructured":"K. Kume, K. Amano, S. Yamada et al., The effect of tocilizumab on BMD in patients with methotrexate-resistant active RA. Rheumatology 53, 900\u2013903 (2014)","journal-title":"Rheumatology"},{"key":"639_CR15","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YPM Goekoop-Ruiterman","year":"2005","unstructured":"Y.P.M. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, C.F. Allaart et al., Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381\u20133390 (2005)","journal-title":"Arthritis Rheum."},{"issue":"6","key":"639_CR16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2007.073817","volume":"67","author":"M G\u00fcler-Y\u00fcksel","year":"2008","unstructured":"M. G\u00fcler-Y\u00fcksel, J. Bijsterbosch, Y.P. Goekoop-Ruiterman et al., Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann. Rheum. Dis. 67(6), 823\u2013828 (2008)","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"639_CR17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.135061","volume":"69","author":"G Schett","year":"2010","unstructured":"G. Schett, K.G. Saag, J.W. Bijlsma, From bone biology to clinical outcome: state of the art and future perspectives. Ann. Rheum. Dis. 69(8), 1415\u20131419 (2010)","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"639_CR18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/ar3375","volume":"13","author":"P Geusens","year":"2011","unstructured":"P. Geusens, W.F. Lems, Osteoimmunology and osteoporosis. Arthritis Res. Ther. 13(5), 242 (2011)","journal-title":"Arthritis Res. Ther."},{"key":"639_CR19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","volume":"156","author":"MF Bakker","year":"2012","unstructured":"M.F. Bakker, J.W. Jacobs, P.M. Welsing et al., Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 156, 329\u2013339 (2012)","journal-title":"Ann. Intern. Med."},{"key":"639_CR20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00198-012-2073-z","volume":"24","author":"MC Goes van der","year":"2013","unstructured":"M.C. van der Goes, J.W.G. Jacobs, M.S. Jurgens et al., Are changes in bone mineral density different between groups of early RA treated to a tight control strategy with or without prednisolone if osteoporosis prophylaxis is applied? Osteoporos. Int. 24, 1429\u20131436 (2013)","journal-title":"Osteoporos. Int."},{"key":"639_CR21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/BOR.0000000000000057","volume":"26","author":"WF Lems","year":"2014","unstructured":"W.F. Lems, P. Geusens, Established and forthcoming drugs for the treatment of osteoporosis. Curr. Opin. Rheumatol. 26, 245\u2013251 (2014)","journal-title":"Curr. Opin. Rheumatol."},{"key":"639_CR22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"S. Wallach, S. Cohen, D.M. Reid, R.A. Hughes, D.J. Hosking, R.F. Laan et al., Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277\u2013285 (2000)","journal-title":"Calcif. Tissue Int."},{"key":"639_CR23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"D.M. Reid, J.P. Devolgelaer, K. Saag et al., Zoledronic acid and risedronate in the prevention and treatment of GIOP (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trail. Lancet 373, 1253\u20131263 (2009)","journal-title":"Lancet"},{"key":"639_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11070","volume":"11","author":"JA Kanis","year":"2007","unstructured":"J.A. Kanis, M. Stevenson, E.V. Mc Closkey et al., Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol. Asses. 11, 1\u2013256 (2007)","journal-title":"Health Technol. Asses."},{"issue":"6","key":"639_CR25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Staa van","year":"2000","unstructured":"T.P. van Staa, H.G. Leufkens, L. Abenhaim et al., Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15(6), 993\u20131000 (2000)","journal-title":"J. Bone Miner. Res."},{"key":"639_CR26","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/art.21194","volume":"52","author":"JR Curtis","year":"2005","unstructured":"J.R. Curtis, A.O. Westfall, J.J. Allison et al., Longitudinal patterns in the prevention of glucocorticoid-treated patients. Arthritis Rheum. 52, 2485\u20132494 (2005)","journal-title":"Arthritis Rheum."},{"key":"639_CR27","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00198-007-0345-9","volume":"18","author":"M Duyvendak","year":"2007","unstructured":"M. Duyvendak, M. Naunton, J. Atthobari et al., Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in the Netherlands 2001\u20132005. Osteoporos. Int. 18, 1429\u20131433 (2007)","journal-title":"Osteoporos. Int."},{"key":"639_CR28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-013-2562-8","volume":"25","author":"C Klop","year":"2014","unstructured":"C. Klop, F. de Vries, T. Vinks et al., Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback. Osteoporos. Int. 25, 385\u2013392 (2014)","journal-title":"Osteoporos. Int."},{"key":"639_CR29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/art.30135","volume":"63","author":"SL Teitelbaum","year":"2011","unstructured":"S.L. Teitelbaum, M.P. Seton, K.G. Saag, Should bisphosphonates be used for longterm treatment of glucocorticoid induced osteoporosis? Arthritis Rheum. 63, 325\u2013328 (2011)","journal-title":"Arthritis Rheum."},{"key":"639_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"E. Shane, D. Burr, B. Abrahamsen et al., Atypical subtrochanteric and diaphyseal fractures: second report of a task force for the ASBMR. J. Bone Miner. Res. 29, 1\u201323 (2014)","journal-title":"J. Bone Miner. Res."},{"key":"639_CR31","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"C.V. Odvina, J.E. Zerwekh, D.S. Rao et al., Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90, 1294\u20131301 (2005)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"639_CR32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00223-009-9263-5","volume":"85","author":"R Armamento-Villareal","year":"2009","unstructured":"R. Armamento-Villareal, N. Napoli, K. Diemer et al., Bone turnover in biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif. Tissue Int. 85(1), 37\u201344 (2009)","journal-title":"Calcif. Tissue Int."},{"key":"639_CR33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00774-014-0591-9","volume":"33","author":"Y Saita","year":"2015","unstructured":"Y. Saita, M. Ishijima, A. Mogami et al., The incidence of and risk factors for developing atypical femoral fractures in Japan. J. Bone Miner. Metab. 33, 311\u2013318 (2015)","journal-title":"J. Bone Miner. Metab."},{"key":"639_CR34","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/ard.2010.143453","volume":"70","author":"CC Mok","year":"2011","unstructured":"C.C. Mok, K.Y. Ying, C.H. To et al., Raloxifene for prevention of glucocorticoid-induced bone loss: a 12\u00a0month randomized double-blinded placebo-controlled trial. Ann. Rheum. Dis. 70, 778\u2013784 (2011)","journal-title":"Ann. Rheum. Dis."},{"key":"639_CR35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00198-011-1758-z","volume":"23","author":"R Rizzoli","year":"2012","unstructured":"R. Rizzoli, R.D. Chapurlat, J.M. Laroche et al., Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2\u00a0year study. Osteoporos. Int. 23, 305\u2013315 (2012)","journal-title":"Osteoporos. Int."},{"issue":"5","key":"639_CR36","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/ard.2009.112920","volume":"69","author":"RK Dore","year":"2010","unstructured":"R.K. Dore, S.B. Cohen, N.E. Lane, W. Palmer, W. Shergy, L. Zhou et al., Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann. Rheum. Dis. 69(5), 872\u2013875 (2010)","journal-title":"Ann. Rheum. Dis."},{"key":"639_CR37","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"K.G. Saag, J.R. Zanchetta, J.P. de Vogelaer et al., Effects of teriparatide versus alendronate for testing glucocorticoid-induced osteoporosis: 36\u00a0months results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346\u20133355 (2009)","journal-title":"Arthritis Rheum."},{"key":"639_CR38","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/jbmr.1870","volume":"28","author":"CC Gluer","year":"2013","unstructured":"C.C. Gluer, F. Marin, J.D. Ringe et al., Comparative effects of teriparatide and risedronate in GIOP in men: 18\u00a0month results of the EuroGIOPs trial. J. Bone Miner. Res. 28, 1365\u20131368 (2013)","journal-title":"J. Bone Miner. Res."},{"key":"639_CR39","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1007\/s00198-013-2379-5","volume":"24","author":"P Farahmand","year":"2013","unstructured":"P. Farahmand, F. Marin, F. Hawkins, Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with GIOP. Osteoporos. Int. 24, 2971\u20132981 (2013)","journal-title":"Osteoporos. Int."},{"key":"639_CR40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11914-011-0085-9","volume":"10","author":"S Boonen","year":"2012","unstructured":"S. Boonen, E. Rosenberg, F. Claessens et al., Inhibition of cathepsin K for treatment of osteoporosis. Curr. Osteoporos. Rep. 10, 73\u201379 (2012)","journal-title":"Curr. Osteoporos. Rep."},{"key":"639_CR41","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","volume":"25","author":"HG Bone","year":"2010","unstructured":"H.G. Bone, M.R. Mc Clung, C. Roux et al., Odanacatib, a cathepsin K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. JBMR 25, 937\u2013947 (2010)","journal-title":"JBMR"},{"key":"639_CR42","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"TD Rachner","year":"2011","unstructured":"T.D. Rachner, S. Khosla, L.C. Hofbauer, Osteoporosis: now and the future. Lancet 377, 1276\u20131287 (2011)","journal-title":"Lancet"},{"key":"639_CR43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR Mc Clung","year":"2014","unstructured":"M.R. Mc Clung, A. Gauer, S. Boonen et al., Romosozumab in postmenopausal women with low BMD. New Engl. J. Med. 370, 412\u2013420 (2014)","journal-title":"New Engl. J. Med."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0639-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-015-0639-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0639-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T10:04:28Z","timestamp":1717927468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-015-0639-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,4]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["639"],"URL":"https:\/\/doi.org\/10.1007\/s12020-015-0639-1","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,4]]}}}